Clinical Trial Update: An Open Label Study to Evaluate G17DT Compared to Gemcitabine [Phase 3]

View source ↗

Summary

The document reports the completion of a Phase 3 open-label trial evaluating G17DT versus gemcitabine in pancreatic cancer. Cancer Advances Inc. is listed as th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• G17DT
• Gemzar (gemcitabine)

Snippet

Sponsor: Cancer Advances Inc. | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED